Genmab A/S (NASDAQ:GMAB) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Genmab A/S (NASDAQ:GMAB) posted its earnings results on Thursday. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.12, FiscalAI reports. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.11 billion. Genmab A/S had a net margin of 21.05% and a return on equity of 15.34%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab raised its 2026 guidance, now expecting revenue of DKK 4.3–4.5 billion and operating profit of DKK 1.1–1.4 billion. Revenue growth at the midpoint is projected at 19%, while operating expenses rise only 2%, highlighting expected operating leverage.
• First-half proprietary-product sales increased 37% to DKK 396 million, led by EPKINLY sales growth of 48% to DKK 312 million. Management cited accelerating U.S. community adoption, broader site activation, and strong uptake of the second-line follicular lymphoma regimen.
• Genmab reported statistically significant, clinically meaningful progression-free-survival results from the phase III EPCORE DLBCL-2 study and received European approval for EPKINLY plus lenalidomide and rituximab in second-line follicular lymphoma.
• Petosemtamab is being expanded into two global phase III colorectal cancer trials—frontline and second-line—in combination with chemotherapy. Management also expects frontline head-and-neck data in the fourth quarter and is positioning the asset as a potential multi-indication growth driver.
• Several major catalysts are expected in the coming quarters, including Rina-S phase II and III ovarian-cancer data and frontline EPKINLY data in the fourth quarter, while petosemtamab’s second- or third-line head-and-neck readout is now expected in the first quarter of 2027. Overall-survival data for the EPKINLY DLBCL study remain immature, and outcomes for these late-stage programs are still subject to clinical and regulatory uncertainty.

Genmab A/S Stock Up 1.9%

Shares of GMAB traded up $0.57 during mid-day trading on Thursday, reaching $29.83. The company’s stock had a trading volume of 5,232,595 shares, compared to its average volume of 1,988,784. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. Genmab A/S has a 12-month low of $21.00 and a 12-month high of $35.43. The stock has a market cap of $18.60 billion, a PE ratio of 22.60, a price-to-earnings-growth ratio of 1.84 and a beta of 0.83. The company’s 50 day moving average is $27.22 and its 200 day moving average is $27.99.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GMAB. New Street Research set a $43.00 target price on Genmab A/S in a report on Wednesday, July 22nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their target price for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Truist Financial began coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Weiss Ratings upgraded Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.28.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GMAB. Parallel Advisors LLC increased its position in Genmab A/S by 11.3% during the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the last quarter. Orion Porfolio Solutions LLC grew its stake in shares of Genmab A/S by 2.3% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock valued at $604,000 after buying an additional 441 shares during the period. Captrust Financial Advisors grew its stake in shares of Genmab A/S by 2.4% during the 2nd quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after buying an additional 526 shares during the period. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after buying an additional 616 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.